NUVB logo

NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

3,067
Mkt Cap
$1.6B
Volume
3.57M
52W High
$9.75
52W Low
$1.57
PE Ratio
-7.67
NUVB Fundamentals
Price
$4.60
Prev Close
$4.63
Open
$4.65
50D MA
$4.98
Beta
1.54
Avg. Volume
5.15M
EPS (Annual)
-$0.5991
P/B
5.08
Rev/Employee
$211,080.54
$2,743.76
Loading...
Loading...
News
all
press releases
Nuvation Bio (NYSE:NUVB) Insider Sells $904,000.00 in Stock
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Kerry Wentworth sold 200,000 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Nuvation Bio (NYSE:NUVB) Insider Kerry Wentworth Sells 200,000 Shares
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Kerry Wentworth sold 200,000 shares of the business's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an...
MarketBeat·3d ago
News Placeholder
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports...
MarketBeat·4d ago
News Placeholder
JPMorgan Chase & Co. Purchases 557,656 Shares of Nuvation Bio Inc. $NUVB
JPMorgan Chase & Co. grew its position in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) by 472.8% in the third quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·6d ago
News Placeholder
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB
Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio Inc. (NYSE:NUVB - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought...
MarketBeat·6d ago
News Placeholder
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PR Newswire NEW YORK, April 2, 2026 NEW YORK, April 2...
PR Newswire·10d ago
News Placeholder
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush
Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Nuvation Bio in a research note on Thursday...
MarketBeat·10d ago
News Placeholder
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo PR Newswire NEW YORK, April 1, 2026 With acquisition of Japan rights, Nuvation Bio now has global development and...
PR Newswire·11d ago
News Placeholder
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB)
Wedbush restated an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a research note on Friday...
MarketBeat·16d ago
News Placeholder
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency...
PR Newswire·17d ago
<
1
2
...
>

Latest NUVB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.